业绩稳健增长，新品研发不断推进

Investment Rating - The report maintains a "Buy" rating for the company [1][25][28] Core Views - The company achieved a revenue of 1.187 billion yuan, representing a year-on-year growth of 32.43%, and a net profit attributable to shareholders of 492.43 million yuan, up 37.98% [13][25] - The company is focused on innovation and has increased its R&D investment by 25.70% to 173 million yuan, with multiple products in the pipeline [14][24] - The company has accelerated its international expansion, with overseas revenue reaching 82 million yuan, a growth of 56.19%, and has entered nine new countries [3][24] Financial Performance - Revenue and profit forecasts for the next few years are optimistic, with projected net profits of 649.34 million yuan in 2024, 831.65 million yuan in 2025, and 1.063 billion yuan in 2026, reflecting growth rates of 31.86%, 28.08%, and 27.84% respectively [25][22] - The company’s earnings per share (EPS) are expected to be 7.85 yuan in 2024, 10.05 yuan in 2025, and 12.85 yuan in 2026 [22][25] - The current price-to-earnings (P/E) ratio is projected to be 23.41 in 2024, decreasing to 14.30 by 2026, indicating a favorable valuation compared to peers [22][25] Product and Market Development - The company has seen strong sales in its aortic stent products, with sales volume reaching 48,664 units and revenue of 940 million yuan, a growth of 28.07% [23] - The company is actively expanding its marketing channels in lower-tier cities, enhancing its market influence [23][24] - The company has successfully submitted registration materials for several innovative products, indicating a robust pipeline for future growth [14][24]